Brainstorm Cell Therapeutics (BCLI) Receives a Buy from H.C. Wainwright


H.C. Wainwright analyst Jason Kolbert maintained a Buy rating on Brainstorm Cell Therapeutics (NASDAQ: BCLI) today and set a price target of $11. The company’s shares closed yesterday at $3.89.

Kolbert wrote:

“We view IP as an important puzzle piece for a business development deal. Office (USPO) has granted a new US patent titled ‘METHODS OF GENERATING MESENCHYMAL STEM CELLS WHICH SECRETE NEUROTROPHIC FACTORS.’ The allowed claims cover the method for generating MSC- NTF cells or NurOwn in industrial amounts for clinical practice. We see this news as a key step as BrainStorm advances NurOwn clinically and on success may choose to partner the product with the right commercial entity.”

According to TipRanks.com, Kolbert ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -4.6% and a 36.6% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Cytori Therapeutics Inc, Anavex Life Sciences, and Coherus Biosciences.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Brainstorm Cell Therapeutics with a $10 average price target, which is a 157.1% upside from current levels. In a report issued on September 13, Maxim Group also maintained a Buy rating on the stock with a $9 price target.

.

See today’s analyst top recommended stocks >>

The company has a one-year high of $5.35 and a one-year low of $2.88. Currently, Brainstorm Cell Therapeutics has an average volume of 70.58K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Brainstorm Cell Therapeutics, Inc. operates as a biotechnology company, which develops and commercializes adult stem cell therapeutic products. It focuses on utilizing the patients own bone marrow stem cells to generate neuron-like cells that may provide an effective treatment initially for amyotrophic lateral sclerosis, Parkinson’s disease, multiple sclerosis and spinal cord injury. The company was founded on September 22, 2000 and is headquartered in New York, NJ.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts